Jpmorgan Chase & CO Alnylam Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,543,770 shares of ALNY stock, worth $2.01 Billion. This represents 0.14% of its overall portfolio holdings.

Number of Shares

4,543,770

Previous 2,218,872 104.78%

Holding current value

$2.01 Billion

Previous $599 Million 245.82%

% of portfolio

0.14%

Previous 0.05%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	BUY	$311.12 - $482.13 $723 Million - $1.12 Billion	2,324,898 Added 104.78%	4,543,770 $2.07 Billion
Q1 2025 May 12, 2025	SELL	$233.07 - $290.7 $7.27 Million - $9.07 Million	-31,188 Reduced 1.39%	2,218,872 $599 Million
Q4 2024 Feb 12, 2025	BUY	$232.27 - $300.43 $20.2 Million - $26.2 Million	87,116 Added 4.03%	2,250,060 $529 Million
Q3 2024 Dec 26, 2024	BUY	$233.81 - $287.01 $91.2 Million - $112 Million	390,073 Added 22.0%	2,162,944 $595 Million
Q3 2024 Nov 08, 2024	BUY	$233.81 - $287.01 $91.2 Million - $112 Million	390,073 Added 22.0%	2,162,944 $595 Million
Q2 2024 Dec 26, 2024	SELL	$143.31 - $247.0 $55.9 Million - $96.3 Million	-390,073 Reduced 18.03%	1,772,871 $431 Million
Q2 2024 Aug 12, 2024	BUY	$143.31 - $247.0 $3.54 Million - $6.1 Million	24,682 Added 1.41%	1,772,871 $431 Million
Q1 2024 Dec 26, 2024	SELL	$146.51 - $198.2 $60.8 Million - $82.2 Million	-414,755 Reduced 19.18%	1,748,189 $261 Million
Q1 2024 May 10, 2024	SELL	$146.51 - $198.2 $186 Million - $251 Million	-1,267,952 Reduced 42.04%	1,748,189 $261 Million
Q4 2023 Dec 26, 2024	BUY	$151.41 - $196.57 $129 Million - $168 Million	853,197 Added 39.45%	3,016,141 $577 Million
Q4 2023 Feb 12, 2024	SELL	$151.41 - $196.57 $10.7 Million - $13.9 Million	-70,705 Reduced 2.29%	3,016,141 $577 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $7.88 Million - $9.76 Million	-46,128 Reduced 1.47%	3,086,846 $547 Million
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $7.07 Million - $8.11 Million	38,240 Added 1.24%	3,132,974 $595 Million
Q1 2023 May 18, 2023	BUY	$182.66 - $235.53 $930,835 - $1.2 Million	5,096 Added 0.16%	3,094,734 $620 Million
Q1 2023 May 11, 2023	SELL	$182.66 - $235.53 $6.95 Million - $8.96 Million	-38,056 Reduced 1.22%	3,089,638 $619 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $108 Million - $141 Million	582,662 Added 22.89%	3,127,694 $743 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $36.2 Million - $60.6 Million	261,395 Added 11.45%	2,545,032 $509 Million
Q2 2022 Aug 11, 2022	SELL	$120.42 - $169.29 $76.5 Million - $108 Million	-635,378 Reduced 21.77%	2,283,637 $333 Million
Q1 2022 May 11, 2022	SELL	$127.18 - $173.91 $6.75 Million - $9.23 Million	-53,070 Reduced 1.79%	2,919,015 $477 Million
Q4 2021 Feb 10, 2022	BUY	$159.56 - $209.29 $84 Million - $110 Million	526,426 Added 21.52%	2,972,085 $504 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $415 Million - $508 Million	2,445,659 New	2,445,659 $462 Million

Others Institutions Holding ALNY

# of Institutions

830

Shares Held

118M

Call Options Held

584K

Put Options Held

648K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $54.5B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Alnylam Pharmaceuticals, Inc. Transaction History